Olmesartan Plus Hct (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Plus Hct, is a angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a diuretic, and is prescribed for adults. GNH USA supplies Olmesartan Plus Hct as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Plus Hct as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Plus Hct is used in the management of cardiovascular conditions that involve the renin‑angiotensin system.

- Hypertension: lowers blood pressure and reduces cardiovascular risk. - Heart failure: assists in controlling fluid balance when combined with a diuretic. - Diabetic nephropathy protection: helps slow progression of kidney damage associated with diabetes.

Common Side Effects: - Dizziness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium)

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Liver enzyme elevation - Blood cell abnormalities such as neutrophil‑low neutropenia

Patients should be evaluated for renal function, electrolyte status, and blood pressure before initiating therapy.

- Monitor renal function: check serum creatinine and eGFR regularly. - Assess electrolytes: watch for potassium and sodium abnormalities. - Avoid in severe hepatic impairment: dose adjustment may be required. - Caution in pregnancy: drugs affecting the renin‑angiotensin system are contraindicated. - Review concomitant antihypertensives: risk of additive blood‑pressure lowering. - Store at ambient temperature: keep in original packaging, protect from moisture.

Olmesartan Plus Hct may interact with several medication classes.

Major Interactions (Avoid): - Potassium‑rich supplements or potassium‑sparing diuretics: risk of hyperkalemia. - Lithium: increased lithium levels and toxicity risk. - NSAIDs: may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives: additive hypotensive effect. - Antidiabetic drugs: may enhance glucose‑lowering effect. - CYP3A4 inhibitors: potential increase in olmesartan exposure.